KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Current Assets (2016 - 2025)

Historic Current Assets for Halozyme Therapeutics (HALO) over the last 17 years, with Q4 2025 value amounting to $825.2 million.

  • Halozyme Therapeutics' Current Assets fell 2396.79% to $825.2 million in Q4 2025 from the same period last year, while for Dec 2025 it was $825.2 million, marking a year-over-year decrease of 2396.79%. This contributed to the annual value of $825.2 million for FY2025, which is 2396.79% down from last year.
  • Halozyme Therapeutics' Current Assets amounted to $825.2 million in Q4 2025, which was down 2396.79% from $1.3 billion recorded in Q3 2025.
  • Halozyme Therapeutics' Current Assets' 5-year high stood at $1.3 billion during Q3 2025, with a 5-year trough of $541.9 million in Q2 2022.
  • In the last 5 years, Halozyme Therapeutics' Current Assets had a median value of $934.0 million in 2021 and averaged $921.3 million.
  • As far as peak fluctuations go, Halozyme Therapeutics' Current Assets surged by 10391.04% in 2021, and later tumbled by 4579.26% in 2022.
  • Over the past 5 years, Halozyme Therapeutics' Current Assets (Quarter) stood at $926.3 million in 2021, then dropped by 20.22% to $739.0 million in 2022, then grew by 1.0% to $746.4 million in 2023, then soared by 45.41% to $1.1 billion in 2024, then fell by 23.97% to $825.2 million in 2025.
  • Its last three reported values are $825.2 million in Q4 2025, $1.3 billion for Q3 2025, and $1.1 billion during Q2 2025.